In a new study published in the JAMA Network Open medical journal, Novo Nordisk A/S’s (NYSE:NVO) Saxenda (liraglutide), an earlier-generation weight loss drug, reveals significant declines in bone density among patients in the hips, spine, and forearm. The study, led by Signe Sørenson Torekov of Copenhagen University, suggests that while these medications effectively reduce weight, they may compromise bone health due to caloric restriction and hormonal changes. 195 participants were randomized, with 48 participants in the exercise group, 49 in the liraglutide group, 49 in the combination group, and 49 in the placebo group. The total estimated mean change in weight loss during the study was 7.03 kg ...